Support: 888-992-3836
Copyright © 2023 InvestorsHub Inc.
Replies to post #213764 on Biotech Values
Titan V
09/22/17 10:23 AM
#213779 RE: DewDiligence #213764
DewDiligence
06/04/18 3:02 PM
#219382 RE: DewDiligence #213764
Aravive Biologics is a privately held clinical stage biopharmaceutical company developing novel, highly selective therapies designed to treat serious cancers and certain fibrotic diseases. Aravive’s lead program is focused on inhibition of the GAS6-AXL signaling axis, which is a known target associated with the growth and proliferation of multiple tumor types. …Aravive has established clinical proof-of mechanism for its first-in-class drug candidate, demonstrating full GAS6 neutralization with AVB-S6-500, and plans to initiate an expanded clinical development program combining it with standard of care therapies in patients with a number of tumor types, initially in ovarian cancers in the second half of 2018. … Following the proposed merger, Versartis and Aravive equity holders are each expected to own approximately 50 percent of the combined company.